Salignostics, a leader in saliva-based rapid tests, has partnered with ARC Innovation from Sheba Medical Center to develop a groundbreaking test for early detection of oral cavity cancer using saliva analysis. With over 400,000 global cases of oropharyngeal cancer annually and a five-year survival rate of only 50%, early detection is crucial. Current detection methods are often inadequate, relying on physical exams and biopsies that catch the disease late.
The partnership, spearheaded by Sheba's Oral and Maxillofacial Surgery Institute and key medical experts, aims to create one of the first saliva-based tests for early oral cancer detection. This method leverages saliva's direct contact with infected tissues to identify disease markers early. Success in this area could lead to similar tests for other cancers, including head and neck cancers.
Salignostics' advanced saliva processing platform, which has already produced rapid tests for pregnancy and COVID-19, underpins this collaboration. Dr. Alex Dobrian of Sheba Medical Center highlighted the potential significant impact of this test on patient recovery and the promising collaboration between Sheba’s expert team and Salignostics’ innovative technology.
Click here to read the original news story.